PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
| Autor: | Yamasaki T; Department of Molecular Probes, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan., Kawamura K, Hatori A, Yui J, Yanamoto K, Yoshida Y, Ogawa M, Nengaki N, Wakisaka H, Fukumura T, Zhang MR |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Nuclear medicine communications [Nucl Med Commun] 2010 Nov; Vol. 31 (11), pp. 985-93. |
| DOI: | 10.1097/MNM.0b013e32833fbf87 |
| Abstrakt: | Objective: To evaluate the functions of P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) in human colon adenocarcinoma (Caco-2), we carried out an in-vitro study and a small animal positron emission tomography (PET) study using [C]GF120918 (elacridar). Methods: [C]GF120918 was synthesized by reacting the desmethyl precursor with [C]CH3I. An in-vitro study using [C]GF120918 was carried out in Caco-2 and Madin-Darby canine kidney cells in the presence or absence of a transporter inhibitor (cyclosporine A and unlabeled GF120918). The biodistribution of radioactivity after the injection of [C]GF120918 was determined in Caco-2-bearing mice using a small animal PET scanner. Results: In Caco-2 cells expressing Pgp and BCRP, coincubation with unlabeled GF120918 caused an approximately two-fold increase in [C]GF120918 uptake compared with that of the control ([C]GF120918 only). In Caco-2-bearing mice, PET results indicated that [C]GF120918 uptake in the tumor was low, but was significantly increased by treatment with unlabeled GF120918. In metabolite analysis, the radioactive component in the tumor almost corresponded to intact [C]GF120918. Conclusion: A PET study combining the administration of [C]GF120918 with unlabeled GF120918 may be a useful tool for evaluating the functions of Pgp and BCRP in tumors. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|